What if we could
cure fatal rare
Rare Monogenic Disease
Many rare diseases are caused by a single mutation in a gene, which leads to a build up of a misfolded, non-functional protein. These proteins go on to do serious damage to the cell and therefore cause often significant disease. And very often they inhibit the ability of the cell to undergo autophagy which itself leads to more damage.
So if we boost autophagy we can remove the misfolded, cytotoxic protein, restore the cell’s ability to undergo autophagy, and in some cases we find that we can also restore the function of the mutated protein. This means restoring autophagy is not just helping an aspect of the disease but is truly curative.
In Samsara we are studying specific rare genetic peripheral nervous system and liver diseases where we believe autophagy can be completely curative.
This could be life-changing for many patients suffering with severe diseases which are currently poorly treated.
We caught up with Senior Scientists Gabriela Vilema Enríquez and Matthew Williamson on their work within the neuroscience team at Samsara.
CMT Research Foundation and Samsara Therapeutics Partner on a Novel Therapeutic Approach for CMT1A with the Potential to Reach Clinical Trials
Hear from Nicole Mak, a Biology student at Bath University, on her year in industry with Samsara.
Michael Schlossmacher, Susan Perlman, Ed Tate and Christian Behl to help advance development of neurodegeneration and rare genetic disease therapeutics